Bioavailability, Biotransformation, and Excretion of the Covalent Bruton Tyrosine Kinase Inhibitor Acalabrutinib in Rats, Dogs, and Humans

Acalabrutinib

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 47; no. 2; pp. 145 - 154
Main Authors Podoll, Terry, Pearson, Paul G, Evarts, Jerry, Ingallinera, Tim, Bibikova, Elena, Sun, Hao, Gohdes, Mark, Cardinal, Kristen, Sanghvi, Mitesh, Slatter, J Greg
Format Journal Article
LanguageEnglish
Published United States American Society for Pharmacology and Experimental Therapeutics, Inc 01.02.2019
Subjects
Absorption
Acrylamide
Benzamide
Bioavailability
Biotransformation
Blood cells
Bruton's tyrosine kinase
Carbon 14
Conjugation
Covalence
Economic conditions
Enzyme inhibitors
Excretion
Glutathione
Half-life
Hydrolysis
Inhibitors
Intravenous administration
Kinases
Liquid chromatography
Low concentrations
Mass spectrometry
Mass spectroscopy
Metabolism
Metabolites
Occupancy
Oxidation
Peripheral blood
Pyrrolidine
Radioactive half-life
Radioactivity
Thioethers
Tyrosine
Tyrosine kinase inhibitors
Urine
Online AccessGet full text

Cover

More Information
Summary:Acalabrutinib
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0090-9556
1521-009X
DOI:10.1124/dmd.118.084459